MMED vs TNDM: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of October 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: MMED is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. MMED and TNDM share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined MMED and TNDM exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

MiniMed Group is Medtronic's former Diabetes business, headquartered in Northridge, California, with about 8,000 employees and products sold in about 80 countries. It makes automated insulin delivery systems (the MiniMed 780G, and since 2026 the smaller MiniMed Flex), MiniMed Go smart insulin pens, Simplera continuous glucose monitors, and sells the Instinct sensor made by Abbott, all tied together by its own algorithms and app. CEO Que Dallara leads the company.

Full MMED guide

Tandem Diabetes Care designs, makes, and sells insulin pumps for people with diabetes. Its flagship products are the t:slim X2 pump and the much smaller Tandem Mobi system, both running Control-IQ+ automated insulin delivery software that reads data from a continuous glucose monitor (CGM) and automatically adjusts insulin dosing. The business works on a razor-and-blade model: Tandem earns an up-front sale when a customer adopts a pump, then recurring revenue from the disposable cartridges, infusion sets, and other supplies that customer buys for years afterward. Pumps integrate with third-party CGMs from Dexcom (G6/G7) and Abbott (FreeStyle Libre), which Tandem does not make itself.

Full TNDM guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• MMED drivers: A full US product cycle; International growth engine.
• TNDM drivers: Recurring supplies and a growing installed base; Tandem Mobi and Control-IQ+ product cycle.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: MiniMed is unprofitable on a GAAP basis (trailing net loss about $314 million, operating cash flow negative) and has a thin cash balance of about $207 million on its latest balance sheet, so execution on the margin plan matters. For TNDM, competition is the central risk: Insulet's tubeless Omnipod 5 is the fastest-growing system in the market, Medtronic remains a large incumbent, and newer entrants like Beta Bionics' iLet and Sequel's twiist add pressure, all of which can squeeze Tandem's pricing and pump share.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick MMED if you believe its drivers more; TNDM if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the MMED and TNDM guides.

MMED. At about 1.5 times sales, MiniMed trades at a steep discount to faster-growing, profitable diabetes-device peers, a gap that reflects its GAAP losses, its recent US share losses and the overhang from Medtronic's exit. On forward earnings the multiple is about 25x. The 15 covering analysts rate it a buy with a mean target near $25, and Rothschild & Co Redburn initiated at buy with a $30 target on October 13, 2026.

TNDM. Tandem is best read as a growth medtech rather than a mature, profitable company, so investors tend to watch pump shipments, installed-base growth, gross margin, and the path to positive adjusted EBITDA rather than a simple P/E ratio. At about 1.1 times trailing sales and roughly $1.2 billion in market value, the shares price in modest expectations for a business that analysts see moving to small profits in 2027; the forward P/E near 107 mostly reflects how thin those projected earnings still are. Third-quarter results on November 5, 2026 come with a consensus of about $265.9 million in revenue and a loss of $0.24 per share.

Headline figures (approximate, October 2026): MMED shows revenue (ttm) ~$3.2 billion; latest quarter up ~17% year over year, gross / operating margin ~57% / ~0.5%, net income (ttm) ~-$314 million; EPS about -$1.53, p/e (forward) ~25x (forward EPS ~$0.69); TNDM shows revenue (ttm) ~$1.04 billion, revenue growth (latest quarter) ~6% year over year (Q2 2026: ~$254.6M), gross margin (ttm) ~56%; operating margin ~-5%, net income (ttm) ~-$63 million; EPS ~-$0.91.

MMED and TNDM are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined MMED and TNDM exposure against your real portfolio. It is not an investment adviser.